T
Takeshi Ueda
Researcher at University of Duisburg-Essen
Publications - 7
Citations - 4922
Takeshi Ueda is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Everolimus & Nivolumab. The author has an hindex of 6, co-authored 6 publications receiving 4065 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Bernard Escudier,Padmanee Sharma,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Howard Gurney,Frede Donskov,K. Peltola,John Wagstaff,Thomas Gauler,Takeshi Ueda,Huanyu Zhao,Ian M. Waxman,Robert J. Motzer +19 more
TL;DR: The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivorumab as a new standard of care across a broad range of patients with previously treated aRCC.
Journal ArticleDOI
CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
Robert J. Motzer,Padmanee Sharma,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Huanyu Zhao,Ian M. Waxman,Bernard Escudier +19 more
TL;DR: A phase III trial of NIVO vs EVE in previously treated patients with advanced or metastatic RCC was halted early as it met its endpoint; superior overall survival (OS) was seen with NIVo vs EVE.
Journal ArticleDOI
Adverse Event Profile and Dose Modification of Everolimus for Advanced Renal Cell Carcinoma in Real-world Japanese Clinical Practice
Masahiro Nozawa,Norio Nonomura,Takeshi Ueda,Kazuo Nishimura,Hiro-omi Kanayama,Tsuneharu Miki,Tatsuya Nakatani,Yoshihiko Tomita,Haruhito Azuma,Toshiaki Yoshioka,Masao Tsujihata,Hirotsugu Uemura +11 more
TL;DR: Dose modification of everolimus might be associated with longer treatment duration in patients with advanced renal cell carcinoma, and interstitial pneumonia was the most frequent cause of discontinuation in patients who discontinuedEverolimus due to intolerability regardless of the dose modification status.
Journal ArticleDOI
CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Li-an Xu,Ian M. Waxman,Padmanee Sharma,CheckMate Investigators +21 more